4163.SR
Unloved QualityAl-Dawaa Medical Services Company · Healthcare · Saudi Arabia · $847M cap · $1.0M/day traded
SAR 37.40 +2.5% · close 5 Nov · scored 7 Nov
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 7 Nov 2026, the MoatMap Score for Al-Dawaa Medical Services Company (4163.SR) is 74/100, ranked against 25,000+ stocks in 38 markets (Quality 61, Value 71, Momentum 39, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT AL-DAWAA MEDICAL SERVICES COMPANY
Read
Al-Dawaa Medical Services Company, together with its subsidiaries, primarily operates as a pharmaceutical retail company in the Kingdom of Saudi Arabia and Kingdom of Bahrain.
FINANCIAL SUMMARY (SAR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.4B | 5.7B | 6.5B | 6.7B | 7.8% | 6.8B | 6.5B | 6.9B | 1.1% |
| EPS (SAR) | 3.59 | 3.87 | 4.13 | 3.79 | 1.8% | 2.22 | 1.97 | 2.55 | -17.9% |
| Shares | 85.0M | 85.0M | 85.0M | 85.0M | 0.0% | 85.0M | — | — | — |
| Debt | 2.6B | 2.3B | 2.1B | 2.3B | -4.6% | 2.5B | — | — | — |
| Equity | 1.1B | 1.2B | 1.3B | 1.5B | 9.8% | — | — | — | — |
| Op CF | 777.5M | 725.7M | 691.6M | 660.0M | -5.3% | 522.2M | — | — | — |
| Inv CF | -282.7M | -168.2M | -106.2M | -163.8M | — | — | — | — | — |
| Fin CF | -346.1M | -642.2M | -592.1M | -472.5M | — | — | — | — | — |
Made a new 52-week low 9 trading days ago, 40% below its 52-week high. The fall has not stopped yet.
Calmer than 84% of stocks we rank over the past year (volatility 24% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4163.SR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| 4163.SR | Al-Dawaa Medical Services Company(you) | $847M | 74 |
| 4164.SR | Nahdi Medical Company | $3.2B | 89 |
| 9600.SR | Qomel Company Limited | $63M | 26 |
| 2070.SR | Saudi Pharmaceutical Industries and Medical Appliances Corporation | $759M | 74 |
| 4019.SR | Specialized Medical Company | $875M | 69 |
| 4007.SR | Al Hammadi Holding Company | $925M | 68 |
| 4009.SR | Middle East Healthcare Company | $563M | 73 |
| 4016.SR | Middle East Pharmaceutical Industries Company | $604M | 80 |
| 2230.SR | Saudi Chemical Holding Company | $1.4B | 79 |
| 4005.SR | National Medical Care Company | $1.2B | 62 |
Peer medians: ROE 15.6% · P/E 16.2x · Gross margin 31.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.